News
News
EuroPCR 2025: Late-Breaking Data Demonstrate Sustained Significantly Lower Event Rates With Elixir Medical’s DynamX® Bioadaptor Over Drug-Eluting Stent Through Three Years
Late-breaking data demonstrate sustained durability of treatment effect with significantly lower TLF rates (2.7% versus 7.2%, p=0.030) and significantly lower rate of Cardiac Death (0.5% versus 3.2%, p=0.033) with DynamX® compared to DES.
Elixir Medical Announces Launch of LithiX™ Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe
Novel IVL technology designed to deliver calcium fragmentation for treatment of moderate to severely calcified coronary artery lesions without requiring an energy source. IVL technology expands company’s innovative product portfolio.
Elixir Medical Named to Fast Company’s Annual List of the World’s Most Innovative Companies of 2025
Elixir Medical’s LithiX HC-IVL system data demonstrate sustained safety and efficacy at six months, as reported at the TCT conference.
Elixir Medical’s LithiX HC-IVL System Data Demonstrate Sustained Safety and Efficacy at Six Months
Elixir Medical’s LithiX HC-IVL system data demonstrate sustained safety and efficacy at six months, as reported at the TCT conference.
Elixir Medical’s DynamX Bioadaptor Demonstrates Significant Improvement Over Contemporary Drug-Eluting Stent in Patients with Acute Coronary Syndrome and Complex Lesion Subsets After Six Months
—Late-breaking 12-month data from INFINITY-SWEDEHEART presented at TCT 2024 further validate bioadaptor’s unique mechanism of action in complex PCI population subsets— —Results of INFINITY-SWEDEHEART trial
TCT 2024: Elixir Medical to Present Clinical Outcomes on Two Transformative Platforms Designed to Advance Cardiovascular Disease Treatment and Intervention
Late-breaking INFINITY-SWEDEHEART Randomized Clinical Trial (RCT) data evaluating DynamX® Coronary Bioadaptor System’s unique mechanism of action among patients with Acute Coronary Syndrome (ACS) and complex lesion subsets.
ESC Congress 2024: INFINITY-SWEDEHEART Trial of Elixir Medical’s DynamX Bioadaptor Meets Primary Endpoint and Clinical Results Confirm Unique Mechanism of Action
Largest randomized data set to date on bioadaptor, with a complex patient population of 2,400 compared to a DES. Primary endpoint of target lesion failure (TLF) non-inferiority at twelve months was met with a low event rate for DynamX despite increased patient complexity.
Elixir Medical to Present Late-Breaking One-Year Primary Outcomes from the 2,400 Patient INFINITY-SWEDEHEART Clinical Trial at ESC Congress 2024
Elixir Medical is presenting one-year clinical outcomes from the 2,400 patient INFINITY-SWEDEHEART Randomized Clinical Trial (RCT) at ESC Congress 2024 in London.
Elixir Medical’s DynamX Sirolimus-Eluting Coronary Bioadaptor System Granted FDA Breakthrough Device Designation for the Treatment of Symptomatic Ischemic Heart Disease
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronary artery disease, specifically to improve coronary luminal diameter, restore hemodynamic modulation, and reduce plaque progression in patients with symptomatic ischemic heart disease.
PMN 1714 Rev A